“Impact of Bulky & Liposomal Secukinumab on Lymphocytes of Psoriatic Patients, to Determine the Improvement in Bioavailability of Secukinumab Nanolipo” (2025) American Journal of Life Science and Innovation, 4(1), pp. 27–35. doi:10.54536/ajlsi.v4i1.3268.